Telix Pharmaceuticals (ASX:TLX) has completed patient enrolment in the IPAX-2 study evaluating TLX101-Tx in newly diagnosed glioblastoma, with the company reporting no dose-limiting toxicities observed to date, according to a Tuesday statement.

The study is a dose-finding trial evaluating TLX101-Tx in combination with standard post-surgical radiotherapy and temozolomide, and it will proceed with follow-up to establish the maximum tolerated dose.

Twelve patients were enrolled in three dose-escalation cohorts across four sites in Australia, Austria, and the Netherlands to assess safety, tolerability, and determine the maximum tolerated dose.

TLX101-Tx is also being evaluated in the ongoing pivotal phase three IPAX BrIGHT trial for recurrent glioblastoma, which is currently enrolling patients across multiple countries.